How did early dialysis machines force hospitals to decide which patients would receive treatment?
The development of the permanent Teflon arteriovenous shunt by Belding Scribner in 1960 made repeated hemodialysis feasible for patients with chronic renal disease, transforming a condition that was previously fatal into a manageable one. However, because this life-saving technology was scarce and expensive, it created a profound challenge regarding the allocation of health care resources.1
Hospitals were forced to confront difficult ethical dilemmas when demand for treatment exceeded the number of available machines. This scarcity necessitated the creation of selection committees to determine which patients would receive access to the limited life-sustaining technology. These decisions were often based on subjective social criteria, raising significant questions about justice and the potential for unfair discrimination in medical practice. This historical scenario remains a foundational case study in bioethics, illustrating how the emergence of advanced medical technology can force society to address the moral implications of prioritizing certain lives over others when resources are limited.2